Guard Therapeutics reports positive results from preclinical studies of the company?s investigational drug ROSgard in experimental animal models of sepsis. Two independent studies conducted at the Karolinska Institute show that ROSgard reduces the harmful effects that occur in both the liver and kidneys when these organs are exposed to a general inflammation and oxidative stress. The studies are part of Guard Therapeutics? strategy to develop ROSgard as a protective treatment against acute kidney injury in several patient segments, initially in patients undergoing open heart surgery. The experimental results, which show that ROSgard protects against serious types of injury to both the liver and kidneys, thus strengthen the company?s future opportunities to expand the clinical use of ROSgard to broader patient groups with great medical need where there are currently no effective treatments. In the studies, which were carried out in collaboration with researchers at the Karolinska Institute in Stockholm, the effect of ROSgard was evaluated in two separate and well-established animal models for sepsis (?blood poisoning?) in rats, a model of lipopolysaccharide-induced inflammation (LPS) and a CLP model (cecal ligation and puncture). In both studies, organ-protective effects of ROSgard were demonstrated based on a number of biomarkers in both the liver (ALT, AST) and kidneys (creatinine, proteinuria).